Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Top picks in ALL from ASH 2020

Josep-Maria Ribera • 9 Dec 2020
ASH 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Bortezomib Inotuzumab ozogamicin Navitoclax Venetoclax

Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, shares his highlights from ASH 2020 in the field of acute lymphoblastic leukemia (ALL). In particular, he discusses trials of novel agents in the frontline setting, including blinatumomab, inotuzumab, venetoclax, navitoclax and bortezomib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Josep-Maria Ribera, has been a speaker, participated in advisory boards and received honoraria from Pfizer, AMGEN, Shire and Ariad; has participated in clinical trials with Pfizer, AMGEN and Ariad; and has received research support from AMGEN.

More from Josep-Maria Ribera

New horizons in Ph+ ALL: the evolving role of bispecific antibodies
1:20
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera • 14 Sep 2026
NGS-MRD assessment and targeted treatment selection in ALL
1:48
NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera • 14 Sep 2026
Reshaping frontline Ph+ ALL: third-generation TKI plus immunotherapy
2:04
Reshaping frontline Ph+ ALL: third-generation TKI plus immunotherapy
Josep-Maria Ribera • 14 Sep 2026
Significant advances made in Ph+ ALL: TKIs, immunotherapy & more
1:55
Significant advances made in Ph+ ALL: TKIs, immunotherapy & more
Josep-Maria Ribera • 27 Feb 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals